Not Yet Recruiting PHASE3 INTERVENTIONAL 2-arm
NCT07309380
Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
Double-blinded Placebo-controlled Multi-center Phase III Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
Sponsor: Shanghai HEP Pharmaceutical Co., Ltd.
Conditions
Hepatitis D, Chronic
Interventions
Hepalatide 2.1mg Placebo of Hepalatide
Updated 1 time since 2026 Last updated: Dec 16, 2025 Started: Apr 30, 2026 Primary completion: Jun 30, 2027 Completion: Aug 31, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE3 trial investigates Hepatitis D, Chronic and is currently actively recruiting participants. Shanghai HEP Pharmaceutical Co., Ltd. leads this study, which shows 1 recorded version since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE3
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Shanghai HEP Pharmaceutical Co., Ltd.
Data source: Shanghai HEP Pharmaceutical Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .